CA
ANIP icon

CSM Advisors’s ANI Pharmaceuticals ANIP Stock Holding History

CSM Advisors’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.35M Buy
100,860
+72,546
+256% +$5.82M 0.18% 139
2026
Q1 		$2.18M Buy
+28,314
New +$2.21M 0.05% 301

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
GACM
Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CSM Advisors's ANIP Position: Q2 2026 in Review

CSM Advisors increased its ANI Pharmaceuticals (ANIP) stake by 256% in Q2 2026, buying an estimated $5.82M and bringing the position to 100,860 shares worth $8.35M. The position accounts for 0.18% of the portfolio, ranked #139.

CSM Advisors first reported a position in ANIP in Q1 2026 and has held it in 2 quarters since. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

  • CSM Advisors held 100,860 shares of ANI Pharmaceuticals worth $8.35M as of Q2 2026.
  • CSM Advisors bought 72,546 ANI Pharmaceuticals shares in Q2 2026, an estimated $5.82M.
  • ANI Pharmaceuticals made up 0.18% of CSM Advisors's portfolio in Q2 2026, its #139 holding.
  • CSM Advisors first reported a position in ANI Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on CSM Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.